We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Expert Opinion / Commentary · June 07, 2018

Ten Practice Changes That I Will Make After Attending ASCO 2018

Written by
Jeffrey J. Kirshner MD, FACP, FASCO

 

Additional Info

  1. Sparano JA, Gray RJ, Wood WC, et al TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score. Paper presented at: American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2018; Chicago, IL. Abstract LBA1.
  2. Kunz PL, Catalano PJ, Nimeiri H, et al. A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211). Paper presented at: American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2018; Chicago, IL. Abstract 4004.
  3. Earl HM, Hiller L, Vallier A-L, et al. PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results. Paper presented at: American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2018; Chicago, IL. Abstract 506.
  4. Hong YS, Kim SY, Lee JS, et al. Long-term results of the ADORE trial: Adjuvant oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX) versus 5-fluorouracil and leucovorin (FL) after preoperative chemoradiotherapy and surgery for locally advanced rectal cancer. Paper presented at: American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2018; Chicago, IL. Abstract 3501.
  5. Gnant M, Pfeiler G, Steger GG, et al. Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial. Paper presented at: American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2018; Chicago, IL. Abstract 500.
  6. Coleman RE, Finkelstein D, Barrios CH, et al. Adjuvant denosumab in early breast cancer: First results from the international multicenter randomized phase III placebo controlled D-CARE study. Paper presented at: American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2018; Chicago, IL. Abstract 501.
  7. Quenet F, Elias D, Roca L, et al. A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. Paper presented at: American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2018; Chicago, IL. Abstract LBA3503.
  8. Mejean A, Escudier B, Thezenas S, et al. CARMENA: Cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in metastatic renal cell carcinoma—Results of a phase III noninferiority trial. Paper presented at: American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2018; Chicago, IL. Abstract LBA3.
  9. Jotte RM, Cappuzzo F, Vynnychenko I, et al. IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. Paper presented at: American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2018; Chicago, IL. Abstract LBA9000.
  10. Borghaei H, Hellmann MD, Paz-Ares LG, et al. Nivolumab (Nivo) + platinum-doublet chemotherapy (Chemo) vs chemo as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC) with <1% tumor PD-L1 expression: Results from CheckMate 227. Paper presented at: American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2018; Chicago, IL. Abstract 9001.
  11. Lopes G, Wu Y-L, Kudaba I, et al. Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study. Paper presented at: American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2018; Chicago, IL. Abstract LBA4.
  12. Noh WC, Lee JW, Nam SJ, et al. Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: The ASTRRA study. Paper presented at: American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2018; Chicago, IL. Abstract 502.
  13. Regan MM, Francis PA, Pagani O, et al. Absolute improvements in freedom from distant recurrence with adjuvant endocrine therapies for premenopausal women with hormone receptor-positive (HR+) HER2-negative breast cancer (BC): Results from TEXT and SOFT. Paper presented at: American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2018; Chicago, IL. Abstract 503.
  14. Conroy T, Hammel P, Hebbar M, et al Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas. Paper presented at: American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2018; Chicago, IL. Abstract LBA4001.

Disclosure statements are available on the authors' profiles:

Further Reading